about
Access to new medications for the treatment of drug-resistant tuberculosis: patient, provider and community perspectivesInfection Control for Drug-Resistant Tuberculosis: Early Diagnosis and Treatment Is the KeyTuberculosis recurrence and mortality after successful treatment: impact of drug resistanceMultidrug-resistant tuberculosis treatment outcomes in Karakalpakstan, Uzbekistan: treatment complexity and XDR-TB among treatment failuresEpidemic levels of drug resistant tuberculosis (MDR and XDR-TB) in a high HIV prevalence setting in Khayelitsha, South AfricaAmbulatory multi-drug resistant tuberculosis treatment outcomes in a cohort of HIV-infected patients in a slum setting in Mumbai, IndiaAdverse events among HIV/MDR-TB co-infected patients receiving antiretroviral and second line anti-TB treatment in Mumbai, IndiaMultidrug resistant pulmonary tuberculosis treatment regimens and patient outcomes: an individual patient data meta-analysis of 9,153 patientsFirst molecular epidemiology study of Mycobacterium tuberculosis in KiribatiWhole genome sequencing reveals complex evolution patterns of multidrug-resistant Mycobacterium tuberculosis Beijing strains in patientsImpact of Xpert MTB/RIF for TB diagnosis in a primary care clinic with high TB and HIV prevalence in South Africa: a pragmatic randomised trialFeasibility, diagnostic accuracy, and effectiveness of decentralised use of the Xpert MTB/RIF test for diagnosis of tuberculosis and multidrug resistance: a multicentre implementation studyDrug-resistant tuberculosis: time for visionary political leadership.Clinical deterioration during antituberculosis treatment in Africa: incidence, causes and risk factors.Wind-driven roof turbines: a novel way to improve ventilation for TB infection control in health facilities.Drug-resistant tuberculosis--current dilemmas, unanswered questions, challenges, and priority needs.Population structure of mixed Mycobacterium tuberculosis infection is strain genotype and culture medium dependent.Evolutionary history and global spread of the Mycobacterium tuberculosis Beijing lineage.Impact of reduced hospitalisation on the cost of treatment for drug-resistant tuberculosis in South Africa.Resistance to fluoroquinolones and second-line injectable drugs: impact on multidrug-resistant TB outcomesTime to ART Initiation among Patients Treated for Rifampicin-Resistant Tuberculosis in Khayelitsha, South Africa: Impact on Mortality and Treatment Success.Long term efficacy of DOTS regimens for tuberculosis: systematic review.Cost per patient of treatment for rifampicin-resistant tuberculosis in a community-based programme in Khayelitsha, South Africa.Sequence analyses of just four genes to detect extensively drug-resistant Mycobacterium tuberculosis strains in multidrug-resistant tuberculosis patients undergoing treatment.Linezolid for the treatment of complicated drug-resistant tuberculosis: a systematic review and meta-analysis.Tuberculosis diagnostics and biomarkers: needs, challenges, recent advances, and opportunities.Outcomes of clofazimine for the treatment of drug-resistant tuberculosis: a systematic review and meta-analysis.Strategies for reducing treatment default in drug-resistant tuberculosis: systematic review and meta-analysis.QTc prolongation and treatment of multidrug-resistant tuberculosis.A systematic review and meta-analysis of the efficacy and safety of N-acetylcysteine in preventing aminoglycoside-induced ototoxicity: implications for the treatment of multidrug-resistant TB.Xpert MTB/RIF versus sputum microscopy as the initial diagnostic test for tuberculosis: a cluster-randomised trial embedded in South African roll-out of Xpert MTB/RIF.Patients' costs associated with seeking and accessing treatment for drug-resistant tuberculosis in South Africa.Community-based treatment of drug-resistant tuberculosis in Khayelitsha, South Africa.Outbreak of multidrug-resistant tuberculosis on Daru Island.Preventive therapy for child contacts of multidrug-resistant tuberculosis: a prospective cohort study.Emergence of extensive drug resistance during treatment for multidrug-resistant tuberculosis.To treat or not to treat? Implementation of DOTS in Central Asia.Risk of acquired drug resistance during short-course directly observed treatment of tuberculosis in an area with high levels of drug resistance.Linezolid in drug-resistant tuberculosis: haste makes waste.The benefits and risks of mathematical modelling in tuberculosis.
P50
Q28084602-B63194AD-E8E2-4C8C-9D15-18D858D5BB2BQ28393098-C03ED77C-5801-4A26-A864-15DBB937720AQ28469052-C01A76F4-E587-470B-A225-381BF7C204EDQ28469334-21E955AB-7A3F-4105-A6E5-385867B1B7AEQ28476143-7A7B70D7-C6F4-4FBD-BCC3-4374BD66828AQ28478204-F20A8892-8270-4FCB-B537-FD886FD7DBA8Q28481249-5C167A1A-1D64-4CBB-BB69-A00581F623B7Q28482730-B5BC782E-D8EF-4108-BBAB-09715C026160Q28485855-F4004C6F-520C-4AA9-8BD3-29D0B754074FQ28536445-2CD0AB3D-67AC-4919-803E-3D7A20AF8EC1Q28545155-9DE7BEB5-D6DF-46E2-B562-9832B4F60E83Q29615717-F476FDF1-4735-4908-9AC2-EBD7B6207D4FQ30428762-32D9F0A7-1A02-48C7-8D27-15EE256D8513Q33547682-46288A2E-2D36-46C0-AC07-F63FE060F2CAQ34130500-89CDE37C-2714-4AEB-A5BA-1B9912734122Q34266001-572C15A1-D58A-427B-9D0F-2B54B07DCF19Q34922107-C9460744-C19D-4D29-81A8-19089CB527E3Q35544538-8D725D12-9914-442B-B9A1-8D5E93FBC95DQ35662072-6092E463-BB55-4673-A06A-72D331A6FDA9Q35805940-8E2748C5-6F0A-40C2-BC5B-76F2B5A24B6BQ35837236-E78BED63-A3CE-4E29-B122-1498A284C6C3Q36482540-B38717C3-2E2B-4228-AB63-1F3EDFCD50E6Q36893640-CCFF8B11-0EF1-4FE9-9A09-ECE95B090CA3Q37274766-FEC2C4D9-622A-4DFC-98C1-73C8EC6C1A02Q37983221-254695A7-3E1E-4397-9891-B79A38ECD89CQ38002002-8F93A78C-B502-4889-91A3-D00E482CF02EQ38051262-46A026EE-A128-4E3C-9C0C-FB0DBB8B266BQ38065028-C4386D85-A26D-40AC-A9D1-C08218FB9870Q38414242-926BF7C0-31F5-4B0E-89E3-1749E983B33FQ38582633-3810BEB4-C918-4CDC-9AB7-9EAC78D8C3C7Q38947214-BAB68C5D-6EE3-4EA6-AAAF-5F113DBA3FE3Q39381653-FD999500-ABA9-4592-9050-432E94EB7887Q40180199-404CCEDC-FAB0-4F28-AFFB-A478580DF512Q40740025-E8E8EF6E-DD30-4162-A03D-DCA06C01EED0Q42246655-5718622D-F895-4992-9368-B06D0E35DD96Q43949976-3A0BE481-0A4F-4B84-BE9F-8C158A2DDA71Q44034630-000A3F82-076C-48F1-959B-DB0EF8663BF3Q44309966-DBD95A07-EFBD-422A-8DA1-470A792E0422Q44771107-034008AA-7126-47E0-B7C2-21B89153C53DQ44970989-B60A0734-0541-438A-8A26-A9A9F036929C
P50
description
hulumtuese
@sq
onderzoeker
@nl
researcher
@en
հետազոտող
@hy
name
Helen Cox
@ast
Helen Cox
@en
Helen Cox
@es
Helen Cox
@sl
هيلين كوكس
@ar
type
label
Helen Cox
@ast
Helen Cox
@en
Helen Cox
@es
Helen Cox
@sl
هيلين كوكس
@ar
prefLabel
Helen Cox
@ast
Helen Cox
@en
Helen Cox
@es
Helen Cox
@sl
هيلين كوكس
@ar
P106
P1153
35228720000
P21
P31
P496
0000-0002-6538-7192